Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
hayward, your memory is faulty. USPTO denied the patent on the ground that lowering trig without raising LDL-C was obvious. However, ApoB reduction saved the day after USPTO considered Kura, hence the MARINE patents were granted.
Slu, "into the partner thing in EU"? Just look at the stock chart of ESPR and see if you still want "the partner thing in EU".
Former McDonald's CEO Easterbrook returns $105M to company, NY Times reports
"Former McDonald's CEO Steve Easterbrook has returned $105M in cash and stock to the company, The New York Times' David Gelles and Julie Creswell report. The settlement with Easterbrook, who was ousted in 2019 for an inappropriate relationship, is one of the largest ever clawbacks of executive compensation, the report notes. In a message to employees, Chairman Enrique Hernandez Jr. said that the company wanted to hold Easterbrook "accountable for his lies and misconduct, including the way in which he exploited his position as C.E.O.," and that this settlement achieved that goal."
JT next?
liz, 2020 JPM Healthcare Conference presentation.
Feb 15th, 2022.
ltro, does Germany's Vazkepa sale, available since 9/1/2021, good only for private insurance or cash-paying patients currently? TIA.
"Have you ever seen a large hospital bill running into the thousands?"
Leaked SoCal hospital records reveal huge, automated markups for healthcare: 575%!
https://www.latimes.com/business/story/2021-12-10/column-healthcare-billing-markups
hay, Judge Hall's opinion came out on August 3rd, 2021 and the hearing was on 5/26/21. That's 10 weeks from hearing till opinion. Judge Andrew's hearing was on Oct 8, 2021, so using the same timeline, his ruling should be around 12/17/2021.
"Usually, the acquiring company sells off when a deal is done."? That's my point. PFE might take comfort on more future acquisitions since the stock price is up today.
ralph, did you email Amarin about your great idea?
PFE is up close to 5%, or $14B in MC, on BO of ARNA which should encourage the company to do more deals.
Cap, can you do a quarter-to-date TRx comparison between Q42021 and Q42020 when you get a chance? TIA.
Amarin Shares Move Higher; DealReporter Highlights Activist Share In Stock
lizzy, great point. That further confirms my belief that Hikma and its attorneys intentionally cropped the table.
Kiwi, that's expected due to the aftermath of Thanksgiving party gathering.
Just tax loss selling pressure continuing until 12/31/2021, hence underperforming IBB and the market until that date.
ralph, please email to Amarin with your clear and easy to understand verbage.
Ns, I think north was referring to the following case,
https://cafc.uscourts.gov/opinions-orders/21-1360.OPINION.12-7-2021_1875206.pdf
He should confirm shortly.
Ns, your link shows three more faint lines in addition to the bolded headline. Look at it again.
Ns, your linked article's headline said GSK has requested the CAFC to deny Teva's en banc request.
Dream panel for marjac's case:
https://cafc.uscourts.gov/opinions-orders/21-1360.OPINION.12-7-2021_1875206.pdf
north, "yesterday’s opinion from CAFC" on what subject? TIA.
could, did you wear a face mask pre and post vaccine?
Tal, I hope you will have a speedy recovery. Were u on Vascepa before contracting covid?
FFS, instead of posting nice graphs and commentaries, you should just post your ETF trades (TQQQ, SQQQ, SPY, QQQ, etc) using your superior TA system. I'll track it for 12 months. If you outperform the market, I'll bow down to you.
Great point Cap. KM mentioned that all Amarin needs to do is start and complete a trial for the new indication to gain that additional 1 out-year which could be in the billions. Perhaps that's what he meant regarding life cycle management.
"the worst single drug rollout in the history of Biotech"? That honor goes to ESPR. It's running out of cash and do a secondary offering today:
Esperion Announces Pricing of $225 Million Public Offering
https://www.nasdaq.com/press-release/esperion-announces-pricing-of-%24225-million-public-offering-2021-12-02
The secondary was priced at $7 but the stock closes at $5.3 today.
Kiwi, the EU 10+1 years exclusivity is based on REDUCE-IT trial results not REDUCE-IT patents which will expire in 2033 (2039?) if still valid.
Invisible Nation – exposing the realities of ASCVD by Novartis:
could, would you please email Dr. Albert Bourla with your post? He is the ONLY person that could realize your dream, not IHUB message board readers.
Bol, tax loss selling period ends 12/31/21.
I don't think Hikma would care about "stability in the formulation" because nobody care: insurance companies, doctors, pharmacists, FDA and patients.
Impressed with AMRN strength today. Lots of buying last hour despite a crashing market, hoping it's Denner and other activitists.
EXAS has never made a dime but trade over $14B in MC.
PFE prepping for V?
From Dew's board:
PFE drops co-promotion of EXAS’ Cologuard:
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001124140/000112414021000101/exas-20211129.htm
Quote:
On November 29, 2021, Exact Sciences Corporation (the “Company”) and Pfizer Inc. (“Pfizer”) entered into an amendment (the “Amendment”) to the Amended & Restated Cologuard Promotion Agreement effective October 6, 2020, by and between the Company and Pfizer (the “Promotion Agreement”).
The Amendment provides that after November 30, 2021, Pfizer will no longer promote the Company’s Cologuard colorectal cancer screening test (the “Product”) to health care providers. As reported on a Form 8-K filed by the Company on September 15, 2021, the Company recently hired approximately 400 former Pfizer sales representatives to promote the Product to health care providers.
The Amendment provides that the Company will pay Pfizer a total of $35,900,000 in three installments during the second, third, and fourth quarters of 2022. The Amendment eliminates the Company’s obligation to pay Pfizer royalties or other fees except for certain media fees, advertising fees, and any detail fees owed to Pfizer for promoting the Product prior to November 30, 2021.
This 8-K was filed two days ago.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166958888
Wow! Had you used your so-called TA system and time wisely, you would be a billionaire by now.
rose, he is talking his own book.
9, this is what judge Andrew said in the his opinion (p.13):
"I am going to solve the Magistrate Judge referral concern by no longer referring the Rule
12(b )( 6) pleading motions ( as distinguished from the § 101 motions to dismiss) to Magistrate
Judges. (For outstanding referrals to Magistrate Judges, of which there are nearly none, I will
adopt whatever they have recommended. There is no reason to continue to waste resources on
this issue.). "
https://www.ded.uscourts.gov/sites/ded/files/opinions/20-1345.pdf
Does his comment bodes well for Amarin Vs Hikma in Judge Andrew's court?
Ns, great found. Judge Andrew's interview must have taken place before Oct 6th when it was before the October 8th's Amarin Vs Hikma hearing. Therefore going into the October 8th hearing, Judge Andrew most likely had already inclined to follow Judge Hall's recommendation. That's great news for us.
Meo, please don't let the door hit you on the way out.